01:05 , Jul 27, 2019 |  BioCentury  |  Politics, Policy & Law

Washington disarray throws drug pricing back into a muddle

While the urgent need for government action to reduce drug prices is the only issue American politicians agree on regardless of their party affiliation or ideology, there is far from a consensus on solutions. Factions...
00:16 , Jul 24, 2019 |  BC Extra  |  Politics & Policy

Senate Finance Committee bill shocks biopharma companies

Biopharma executives are worrying about a nightmare scenario in which new drug pricing legislation, combined with an international reference pricing scheme, importation and additional price controls, would deal the industry what they perceive as a...
22:02 , Jun 28, 2019 |  BioCentury  |  Product Development

How small companies can leverage big changes in rare diseases

Small companies bring to the table a range of advantages over large ones when it comes to rare diseases, according to Ovid CEO Jeremy Levin. But he’s learned the hard way that it doesn’t help...
23:32 , Jun 26, 2019 |  BC Extra  |  Politics & Policy

HELP Committee advances transparency bill

The Senate Health, Education, Labor and Pensions Committee Wednesday added the Fair Accountability and Innovative Research Drug Pricing Act , a bill that would force drug companies to make extensive disclosures to justify price increases,...
02:03 , Jun 15, 2019 |  BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day Congressional...
23:45 , Jun 14, 2019 |  BioCentury  |  Politics, Policy & Law

No more crickets: The biopharma industry must speak out against the Trump administration’s fetal tissue ban

When President Donald Trump considered a range of options about regulating the use of fetal tissue in medical research, he made a simple political calculation. A ban would solidify support from religious anti-abortion advocates, while...
21:57 , Jun 10, 2019 |  BC Extra  |  Politics & Policy

Stakeholders back Medicare Part D out-of-pocket cap, call for additional changes to lower patient costs

The biopharmaceutical industry, patient groups, PBMs and other stakeholders have endorsed proposals to cap out-of-pocket drug costs for Medicare Part D beneficiaries in comments submitted to the House Ways and Means and Energy and Commerce...
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
19:40 , Jun 4, 2019 |  BC Extra  |  Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
21:36 , Jun 3, 2019 |  BC Extra  |  Company News

Management tracks: Zai, Jazz, PTC, BIO and more

Cancer company Zai Lab Ltd. (NASDAQ:ZLAB) hired Valeria Fantin as its first CSO. She was CSO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Cancer and neurology company Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hired Robert Iannone...